
The demerger follows the group’s acquisition of DHFL for Rs.34,250 crore, which was completed in September 2021.
Addressing shareholders in the company’s annual report for 2021-22, Piramal said the company’s pharma vertical is expected to have nearly…
According to the contours of the agreement, the pharmaceuticals business would be demerged from PEL and consolidated under Piramal Pharma.…
In October last year, Piramal Enterprises Ltd has approved the demerger of its pharmaceutical business – Piramal Pharma (PPL) via…
Under the insolvency resolution proceedings for the crisis-hit DHFL, Piramal Capital had emerged as the winning bidder and the Committee…
Piramal Enterprises today reported a consolidated net profit of Rs 321.71 crore and net sales at Rs 1,847.71 crore for…
The investment will be made in two tranches